Results 81 to 90 of about 418,673 (161)
X-ray crystallography reveals insulin lisargine structure and mechanisms of glucose regulation
Scientific ReportsThe development of effective and safe insulin analogs remains pivotal in advancing diabetes management. This study addresses the limitations of existing insulin therapies by introducing insulin lisargine, a novel long-acting insulin analog that resolves ...
Zhu Zhu +6 more
doaj +1 more source
Journal of Diabetes Research, 2018 To achieve good metabolic control in diabetes and maintain it in the long term, a combination of changes in lifestyle and pharmacological treatment is necessary.
Hernando Vargas-Uricoechea
doaj +1 more source
Medication of the month. Insulin glargine (Lantus)
, 2004 peer reviewedInsulin glargine (Lantus) is a human insulin analogue produced by recombinant DNA technology and recently launched by Aventis. Modification of the human insulin molecule at position A21 and at the C-terminus of the B-chain results in the ...
Scheen, André
core
Insulin Glargine U-300 in Type 1 Diabetes Mellitus: Single-Center Experience
Aim: This study aimed to evaluate the clinical outcomes of switching from first-generation basal insulins to insulin glargine U-300 (Gla-300) in individuals with type 1 diabetes mellitus (T1DM) under real-world conditions.
Siva, Zeynep Osar +3 more
core +1 more source
Cost Effectiveness and Resource AllocationBackground Type 1 Diabetes Mellitus (T1DM) is a life-threatening condition that is managed with administered insulin. Intermediate- to long-acting insulin represents the basal insulin constituent of the total insulin used in treating T1DM.
Mark T. Verryn, Susan Cleary
doaj +1 more source
Forest plot: comparison of insulin glargine vs. non-glargine insulins and risk of prostate cancer.
, 2013 Forest plot: comparison of insulin glargine vs. non-glargine insulins and risk of prostate cancer.
Juan Zhou (207536) +3 more
core +1 more source
European Journal of Medical ResearchAims To examine the effects of administering detemir and glargine insulin on the detection of endogenous C-peptide and insulin levels. Methods This study enrolled 69 patients with type 2 diabetes (T2DM) who use long-acting insulin therapy.
Yi-ting Wang +4 more
doaj +1 more source
Nanoparticles formulations of insulin glargine: an overview [PDF]
Insulin glargine, a long-acting insulin analog, is a cornerstone in the management of diabetes mellitus. However, its therapeutic efficacy is often hindered by limitations such as variable pharmacokinetics and suboptimal bioavailability.
Satinder Kakar, Anjana Rana
core +1 more source
Concentrated insulins: the new basal insulins
Therapeutics and Clinical Risk Management, 2016 Elizabeth M Lamos,1 Lisa M Younk,2 Stephen N Davis3 1Division of Endocrinology, Diabetes and Nutrition, 2Department of Medicine, University of Maryland School of Medicine, 3Department of Medicine, University of Maryland Medical Center, Baltimore, MD ...
Lamos EM, Younk LM, Davis SN
doaj
Economic analysis of Lixisenatide in Diabetes Mellitus Type 2
Качественная клиническая практика, 2018 Usage of glucagon like peptide-1 receptors’ agonists (aGLP-1) is a new step in the treatment of Diabetes Mellitus Type 2 (DM 2). General attractive effects are positive effect on bodyweight, lower risk of hypoglycemia, compliance and possibility of ...
A. S. Kolbin +5 more
doaj